- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Cancer With Transdermal Accessible Tumour in India
Total 16 results
-
Tata Memorial HospitalCompleted
-
PfizerCompletedBreast Cancer | Breast Neoplasms | Breast Tumors | Breast Carcinoma | Cancer of BreastIndia
-
Sanjay Gandhi Postgraduate Institute of Medical...RecruitingBreast Cancer | Tumor Infiltrating Lymphocytes | Programmed Cell Death Ligand 1India
-
Hospital del Río HortegaRecruitingGlioma | Glioblastoma | Brain Neoplasms | Brain Cancer | Brain TumorItaly, Spain, India
-
Tata Memorial HospitalUniversity of ArizonaUnknown
-
International Agency for Research on CancerRajiv Gandhi Centre for Biotechnology; Department of Health and Family welfare... and other collaboratorsRecruiting
-
AstraZenecaDaiichi Sankyo Co., Ltd.Active, not recruitingPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerBelgium, United States, Poland, India, Taiwan, Thailand, Korea, Republic of, Czechia, Russian Federation, United Kingdom, Spain, Australia, Canada, Italy, Netherlands
-
CytRxTerminatedStage IV Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer With Pleural EffusionUnited States, Mexico, India, Ukraine, Bulgaria, Russian Federation
-
Puma Biotechnology, Inc.CompletedBreast Neoplasms | Advanced Breast Cancer | Advanced Malignant Solid TumorsUnited States, Belgium, China, Hong Kong, Canada, Korea, Republic of, India, Poland, Ukraine
-
Genzyme, a Sanofi CompanyActive, not recruitingMedullary Thyroid Cancer | Locally Advanced or Metastatic Medullary Thyroid CancerAustralia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Finland, Germany, Greece, India, Israel, Italy, Korea, Republic of, Poland, Russian Federation, Sweden, United Kingdom
-
Aristotle University Of ThessalonikiNot yet recruitingMedullary Thyroid CancerChina, Switzerland, Spain, Greece, United States, Austria, Belgium, Brazil, Bulgaria, Colombia, Croatia, France, India, Iraq, Italy, Jordan, Morocco, Poland, Serbia, Slovakia, Thailand, Turkey, Ukraine, Vietnam
-
Genzyme, a Sanofi CompanyActive, not recruitingThyroid CancerUnited States, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Hungary, India, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Romania, Russian Federation, Serbia, Spain, Sweden, Switz...
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial ComponentUnited States, Canada, Australia, Israel, Taiwan, United Kingdom, Belgium, France, Spain, Germany, Austria, Brazil, Colombia, Czechia, Greece, Hungary, India, Italy, Mexico, Netherlands, New Zealand, Peru, Switzerland, Thailand
-
Novartis PharmaceuticalsRecruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationItaly, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom
-
Loxo Oncology, Inc.Eli Lilly and CompanyActive, not recruitingMedullary Thyroid CancerUnited States, Canada, Spain, China, Taiwan, Australia, Japan, India, Belgium, Germany, France, Netherlands, Czechia, Brazil, Korea, Republic of, United Kingdom, Italy, Israel, Greece, Poland, Russian Federation
-
RECORDATI GROUPActive, not recruitingProstate Cancer | Neuroendocrine Tumors | Acromegaly | Cushing's Disease | Dumping Syndrome | Pituitary Tumors | Ectopic ACTH Secreting (EAS) Tumors | Melanoma Negative for bRAF | Melanoma Negative for nRASBelgium, Brazil, Bulgaria, Canada, France, Germany, Italy, Japan, Korea, Republic of, Thailand, Turkey, United States, Argentina, Greece, Hungary, India, Israel, Malaysia, Mexico, Netherlands, Peru, Poland, Portugal, Romania, Russian Federation and more